AI Article Synopsis
- - Imatinib has transformed the treatment landscape for gastrointestinal stromal tumors (GISTs), significantly enhancing survival rates for patients with metastatic and locally advanced disease compared to older therapies.
- - Recent research focuses on optimizing imatinib usage by examining factors like timing, total dosage, and therapy duration, along with the influence of different genotypes on treatment response.
- - The review highlights the best practices for using imatinib in both adjuvant and metastatic scenarios, including dosage adjustments based on genetic factors, the length of treatment, and ongoing clinical trials exploring its efficacy.
Article Abstract
Imatinib therapy has revolutionized the treatment of patients with gastrointestinal stromal tumors (GISTs). Compared with older therapy, imatinib significantly improves outcomes in patients with metastatic disease and those with locally advanced tumors, raising progression-free and overall survival. Recent studies have evaluated variables such as timing of treatment, total dosing, and duration of therapy. Different genotypes are associated with a poorer response to imatinib therapy, whereas others may benefit from a higher starting dose. This review discusses recent data regarding optimal use of imatinib for treatment of GIST in both the adjuvant and metastatic settings, and addresses topics such as the impact of genotype on initial dose, dose escalation, optimal duration of treatment, and neoadjuvant therapy. Key ongoing clinical trials of imatinib in GIST are also discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574884710666151020100518 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!